看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | 12.5x - 13.8x | 13.1x |
| Selected Fwd EBIT Multiple | 6.1x - 6.7x | 6.4x |
| Fair Value | $5.11 - $6.49 | $5.80 |
| Upside | -30.5% - -11.8% | -21.1% |
| Benchmarks | Ticker | Full Ticker |
| Amphastar Pharmaceuticals, Inc. | AMPH | NasdaqGS:AMPH |
| Supernus Pharmaceuticals, Inc. | SUPN | NasdaqGM:SUPN |
| ANI Pharmaceuticals, Inc. | ANIP | NasdaqGM:ANIP |
| TherapeuticsMD, Inc. | TXMD | NasdaqGS:TXMD |
| Indivior PLC | INDV | NasdaqGS:INDV |
| Amneal Pharmaceuticals, Inc. | AMRX | NasdaqGS:AMRX |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| AMPH | SUPN | ANIP | TXMD | INDV | AMRX | ||
| NasdaqGS:AMPH | NasdaqGM:SUPN | NasdaqGM:ANIP | NasdaqGS:TXMD | NasdaqGS:INDV | NasdaqGS:AMRX | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | NM- | -16.2% | -2.3% | NM- | 7.6% | NM- | |
| 3Y CAGR | 42.0% | -8.3% | NM- | NM- | 16.0% | 17.2% | |
| Latest Twelve Months | 2.9% | 357.8% | -70.5% | 59.0% | 12.3% | 28.4% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | 18.1% | 15.5% | -1.2% | -297.9% | 19.8% | 9.3% | |
| Prior Fiscal Year | 31.0% | 2.2% | 10.2% | -654.6% | 23.8% | 11.3% | |
| Latest Fiscal Year | 28.1% | 9.3% | 2.4% | -198.3% | 24.6% | 12.5% | |
| Latest Twelve Months | 28.1% | 9.3% | 2.4% | -198.3% | 24.6% | 12.5% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 2.11x | 1.96x | 3.11x | 7.84x | 0.98x | 1.74x | |
| EV / LTM EBITDA | 6.0x | 9.2x | 23.2x | -4.6x | 3.7x | 8.3x | |
| EV / LTM EBIT | 7.5x | 21.1x | 130.7x | -4.0x | 4.0x | 13.9x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | -4.0x | 7.5x | 130.7x | ||||
| Historical EV / LTM EBIT | 13.9x | 16.6x | 29.6x | ||||
| Selected EV / LTM EBIT | 12.5x | 13.1x | 13.8x | ||||
| (x) LTM EBIT | 348 | 348 | 348 | ||||
| (=) Implied Enterprise Value | 4,344 | 4,573 | 4,801 | ||||
| (-) Non-shareholder Claims * | (2,510) | (2,510) | (2,510) | ||||
| (=) Equity Value | 1,835 | 2,063 | 2,292 | ||||
| (/) Shares Outstanding | 313.4 | 313.4 | 313.4 | ||||
| Implied Value Range | 5.85 | 6.58 | 7.31 | ||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 5.85 | 6.58 | 7.31 | 7.36 | |||
| Upside / (Downside) | -20.5% | -10.5% | -0.6% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | AMPH | SUPN | ANIP | TXMD | INDV | AMRX | |
| Enterprise Value | 1,531 | 1,298 | 1,905 | 14 | 1,151 | 4,816 | |
| (+) Cash & Short Term Investments | 222 | 454 | 151 | 5 | 320 | 112 | |
| (+) Investments & Other | 11 | 0 | 5 | 0 | 27 | 36 | |
| (-) Debt | (651) | (34) | (631) | (7) | (374) | (2,593) | |
| (-) Other Liabilities | 0 | 0 | 0 | 0 | 0 | (65) | |
| (-) Preferred Stock | 0 | 0 | (25) | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 1,113 | 1,717 | 1,405 | 12 | 1,124 | 2,306 | |
| (/) Shares Outstanding | 47.7 | 55.8 | 20.3 | 11.6 | 124.8 | 313.4 | |
| Implied Stock Price | 23.35 | 30.76 | 69.21 | 1.01 | 9.01 | 7.36 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 23.35 | 30.76 | 69.21 | 1.01 | 9.01 | 7.36 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |